Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BIAF | 8-K | bullish | 5/10 | bioAffinity Technologies filed an 8-K announcing that Q2 2026 CyPath Lung test sales volume more than doubled year-over- | Jul 7, 2026 |
| ONCO | 425 | neutral | 2/10 | Onconetix highlights a new partnership between its acquisition target Realbotix and Bloom Services for a UK pilot deploy | Jul 7, 2026 |
| SNY | 6-K | bullish | 5/10 | Sanofi reported positive phase 3 results for Nexviazyme (avalglucosidase alfa) in infantile-onset Pompe disease (IOPD). | Jul 7, 2026 |
| LYB | PRESS-RELEASE | neutral | 2/10 | LyondellBasell announced a collaboration with Mondelez, Amcor, and Taghleef to produce flexible packaging for Marabou ch | Jul 7, 2026 |
| GRTX | 8-K | bearish | 6/10 | Galera Therapeutics announced a 1-for-200 reverse stock split, effective July 12, 2026, with split-adjusted trading star | Jul 7, 2026 |
| MGTX | 8-K | bullish | 8/10 | MeiraGTx entered into a $400M strategic financing with Oberland Capital, including up to $375M in non-dilutive royalty n | Jul 7, 2026 |
| CMPS | 8-K | neutral | 3/10 | Analysis based on filing metadata only, document content was unavailable. COMPASS Pathways filed an 8-K with items 7.01 | Jul 7, 2026 |
| AXSM | PRESS-RELEASE | neutral | 4/10 | Axsome announced the first patient dosed in the FOCUS-2 Phase 3 trial of solriamfetol for children with ADHD, a 468-pati | Jul 7, 2026 |
| AGIO | PRESS-RELEASE | bullish | 7/10 | Agios announced FDA Priority Review acceptance of its sNDA for mitapivat in sickle cell disease, with a PDUFA goal date | Jul 7, 2026 |
| OKYO | 6-K | neutral | 2/10 | OKYO Pharma announced its participation in a fireside chat at the Piper Sandler Virtual Ophthalmology Symposium on July | Jul 7, 2026 |
| WST | PRESS-RELEASE | neutral | 1/10 | West Pharmaceutical Services, Inc. announced it will host a conference call on July 23, 2026 to discuss its Q2 2026 resu | Jul 7, 2026 |
| NUVL | CLUSTER | neutral | 3/10 | Two C-suite executives at Nuvalent (CFO and CDO) sold a combined $2.09M in open-market shares this week, all on the same | Jul 7, 2026 |
| VRTX | CLUSTER | neutral | 2/10 | Two VRTX C-suite executives (CMO and Chief Legal Officer) sold a combined ~$704K in open-market sales over a one-week wi | Jul 7, 2026 |
| ZLAB | CLUSTER | neutral | 2/10 | Three insiders at Zai Lab (CEO, CLO, CFO) sold a net ~$242K in open-market shares over a 5-day window ending June 30, 20 | Jul 7, 2026 |
| SRRK | CLUSTER | neutral | 2/10 | Two directors at Scholar Rock sold a combined ~$124K in open-market transactions on July 1, 2026, representing ~0.002% o | Jul 7, 2026 |
| ALKS | CLUSTER | neutral | 2/10 | Two Alkermes executives, the EVP/CLO and the EVP R&D/CMO, sold a combined $537K in open-market shares near $52-54, repre | Jul 7, 2026 |
| CSTL | CLUSTER | neutral | 3/10 | CEO Derek Maetzold and COO Kristen Oelschlager sold a combined $351K in open-market shares on July 1, 2026. The CEO's sa | Jul 7, 2026 |
| ABSI | INSIDER-BUY | neutral | 2/10 | Director Mary T. Szela purchased $149K of Absci Corp (ABSI) shares at $11.54 on June 30, 2026. The purchase is trivial r | Jul 7, 2026 |
| IBRX | CLUSTER | neutral | 2/10 | Two directors of ImmunityBio sold a combined ~$2.7M in open-market stock this week, following derivative exercises. The | Jul 7, 2026 |
| BOLD | CLUSTER | neutral | 4/10 | Two 10% owners at Boundless Bio (BOLD) traded in opposite directions in the same window: Kevin Tang bought ~$203K worth | Jul 7, 2026 |
| ADPT | CLUSTER | neutral | 4/10 | A cluster of insider selling at Adaptive Biotechnologies has emerged in a two-week window ending July 2, 2026, totaling | Jul 6, 2026 |
| PCVX | CLUSTER | neutral | 2/10 | Two C-suite insiders at Vaxcyte (PCVX) sold shares worth $478K in the past week, but the amount is negligible relative t | Jul 6, 2026 |
| PCVX | CLUSTER | neutral | 2/10 | Insider selling cluster at Vaxcyte (PCVX): CEO Grant Pickering sold $363K and COO Jim Wassil sold $26K in open-market tr | Jul 6, 2026 |
| IONS | CLUSTER | neutral | 3/10 | Multiple IONS insiders including CEO Brett Monia sold shares totaling $7.67M over a 7-day window. However, the total rep | Jul 6, 2026 |
| ABCL | 3 | neutral | 1/10 | Lynn Seely filed a Form 3 indicating initial beneficial ownership of zero shares in AbCellera Biologics. This is a routi | Jul 6, 2026 |
| HYEX | 8-K | bearish | 5/10 | Kevin Duke Pitts resigned as President, Chief Operating Officer, and board member effective July 1, 2026. No replacement | Jul 6, 2026 |
| PBYI | 144 | neutral | 2/10 | CEO Alan Auerbach files Form 144 to sell 44,058 shares, currently worth approximately $364K, to cover a tax withholding | Jul 6, 2026 |
| GLUE | CLUSTER | neutral | 3/10 | Two insiders at Monte Rosa Therapeutics sold a total of $364K in open-market sales over a 7-day window, including the Ch | Jul 6, 2026 |
| IMVT | CLUSTER | neutral | 3/10 | Five Immunovant insiders (CFO, CTO, CLO, COO, and a director) collectively sold ~$2.4M in open-market shares on June 26, | Jul 6, 2026 |
| CRVO | S-3 | bearish | 6/10 | CervoMed filed an S-3 shelf registration to register 10,081,131 shares of common stock for resale by selling stockholder | Jul 6, 2026 |